Product category:
Laboratory and scientific exhibitions and conferences
News Release from: Select Biosciences | Subject: Secondary Screening 2003
Edited by the Laboratorytalk Editorial
Team on 10 October 2003
Growing market for ADME and toxicology
According to a new report, the market for in vitro toxicology is expected to grow to more than $300 million by 2005
Secondary Screening 2003 presents a quantitative market model segmented by re-screening, toxicology, and ADME It includes detailed assessment of competitive landscape, including 40 company evaluations, and analysis of key drivers and trends in a complex and dynamic industry
This article was originally published on Laboratorytalk on 7 May 2003 at 8.00am (UK)
Related stories
Protein biochip market remains wide open
Market report is based on extensive primary and secondary research, including interviews with current and potential customers and interviews with company representatives
Proteomics market shows rapid growth
Market research report projects that the market will grow to more than $2.5 billion by 2008, a compound annual growth rate of more than 14%
90% of compounds fail in drug development because of four reasons.
41% of those fail because of poor ADME, 31% because of insufficient efficacy, 22% because of toxicity, and only 6% because of market and/or commercialisation complications.
The earlier in the development process that an inadequate compound can be removed, the less time and money wasted, usually on the order of five to ten years and hundreds of millions of dollars.
The triage process thus represents a large opportunity with significant unmet needs, and new technologies are defining and expanding this market.
Triage starts immediately after primary high-throughput screening, and the market opportunity for re-screening of hits is approximately $190 million worldwide and expected to grow to more than $250 million by 2005.
The market opportunities for toxicology and ADME currently total approximately $3 billion, most of which is spent on animal studies.
The market for in vitro toxicology testing, the segment within secondary screening, is approximately $200 million and expected to grow more than $300 million by 2005.
The growth within all three of these segments is driven by a diverse set of new technologies, including high-content screening platforms and cellular models of toxicology and metabolism.
Most of these technologies are distributed across more than 40 companies, but a significant amount of industry consolidation is expected over the next two years to integrate instruments, reagents, and informatics/data management solutions.
Navigating this dynamic competitive landscape and emerging market requires business intelligence.
Secondary Screening 2003 is produced by Select Biosciences, an international biotechnology business consulting firm that specialises in drug discovery technologies.
• Select Biosciences: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
